3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 1/2
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Follicular
2
Pyloric Stenosis, Hypertrophic
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Rituximab
48
Cyclophosphamide
27
Lenalidomide
23
Peripheral Blood Stem Cell Transplantation
16
obinutuzumab
10
fludarabine phosphate
10
Filgrastim
10
Etoposide
10
Bendamustine Hydrochloride
10
Vincristine
8
Prednisone
8
Doxorubicin
8
fludarabine
7
Radiotherapy
7
Mycophenolic Acid
7
Melphalan
7
Cyclosporine
7
Bortezomib
7
venetoclax
6
tazemetostat
6
ibritumomab tiuxetan
6
Whole-Body Irradiation
6
Gemcitabine
6
pembrolizumab
5
ibrutinib
5
Ifosfamide
5
Granulocyte Colony-Stimulating Factor
5
CT-P10
5
veltuzumab
4
Methotrexate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, Follicular
×
R-CHOP protocol
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled